James P. Agalloco - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

James P. Agalloco


James P. Agalloco Pharmtech editorial advisory board (EAB) member

James P. Agalloco
President,
Agalloco & Associates

Agalloco is a past president of the Parenteral Drug Association (PDA) and served as an officer or director of PDA from 1982 to 1993. He has authored or co-authored more than 90 papers and lectured extensively on sterilization, aseptic processing, and validation at various PDA, PMA, the International Society for Pharmaceutical Engineering (ISPE), and Pharmaceutical Technology meetings, domestically as well as internationally. He is a member of USP’s Microbiology and Sterility Assurance Expert Committee for 2005–2010. Agalloco is a member of the editorial advisory boards of Pharmaceutical Technology and Pharmaceutical Manufacturing, and serves on the scientific advisory boards of Laureate, MEDInstill, MODA, and IPS.

He is a frequent author and lecturer on the subject of sterilization, aseptic processing, and process validation.

James Agalloco is president of Agalloco & Associates, which provides a range of technical services to the pharmaceutical and biotechnology industry. Since the formation of the company in 1991, Agalloco has assisted more than 100 healthcare firms in a wide range of validation, automation and compliance areas. During his more than 35 years of industry experience, he has worked in organic synthesis, pharmaceutical formulation, pharmaceutical production, project and process engineering, validation and process automation during his career at Merck, Pfizer, Squibb and Bristol-Myers Squibb.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here